Treatment of tardive dyskinesia: a review and update for dermatologists managing delusions of parasitosis

References

• Beck KM, Bhutani T, Koo JYM. Comprehensive dermatologic drug therapy. 4th ed. Amsterdam (The Netherlands): Elsevier. p. 382–396.
   Google Scholar
• Citrome L. Tardive dyskinesia: placing vesicular monoamine transporter type 2 (VMAT2) inhibitors into clinical perspective. Expert Rev Neurother. 2018;18(4):323–332.
   PubMed Web of Science ®Google Scholar
• Andreassen OA, Jørgensen HA. Neurotoxicity associated with neuroleptic-induced oral dyskinesias in rats. Implications for tardive dyskinesia? Prog Neurobiol. 2000;61(5):525–541.
   PubMed Web of Science ®Google Scholar
• Munyon WH, Salo R, Briones DF. Cytotoxic effects of neuroleptic drugs. Psychopharmacology. 1987;91(2):182–188.
   PubMed Web of Science ®Google Scholar
• Yassa R. Functional impairment in tardive dyskinesia: medical and psychosocial dimensions. Acta Psychiatr Scand. 1989;80(1):64–67.
   PubMed Web of Science ®Google Scholar
• van Os J, Fahy T, Jones P, et al. Tardive dyskinesia: who is at risk? Acta Psychiatr Scand. 1997;96(3):206–216.
   PubMed Web of Science ®Google Scholar
• Solmi M, Pigato G, Kane JM, et al. Clinical risk factors for the development of tardive dyskinesia. J Neurol Sci. 2018;389:21–27.
   PubMed Web of Science ®Google Scholar
• Cornett EM, Novitch M, Kaye AD, et al. Medication-induced tardive dyskinesia: a review and update. Ochsner J. 2017;17(2):162–174.
   PubMed Web of Science ®Google Scholar
• Wijemanne S, Jankovic J, Evans RW. Movement disorders from the use of metoclopramide and other antiemetics in the treatment of migraine. Headache. 2016;56(1):153–161.
   PubMed Web of Science ®Google Scholar
• Sandler NH. Tardive dyskinesia associated with fluoxetine. J Clin Psychiatry. 1996;57(2):91.
   PubMed Web of Science ®Google Scholar
• Zadikoff C, Munhoz RP, Asante AN, et al. Movement disorders in patients taking anticonvulsants. J Neurol Neurosurg Psychiatry. 2007;78(2):147–151.
   PubMed Web of Science ®Google Scholar
• Barone DA, Raniolo J. Facial dyskinesia from overdose of an antihistamine. N Engl J Med. 1980;303(2):107.
   PubMed Web of Science ®Google Scholar
• Clark BG, Araki M, Brown HW. Hydroxyzine-associated tardive dyskinesia. Ann Neurol. 1982;11(4):435.
   PubMed Web of Science ®Google Scholar
• Thomson AM, Wallace J, Kobylecki C. Tardive dyskinesia after drug withdrawal in two older adults: clinical features, complications and management. Geriatr Gerontol Int. 2019;19(6):563–564.
   PubMed Web of Science ®Google Scholar
• Kim J, Macmaster E, Schwartz TL. Tardive dyskinesia in patients treated with atypical antipsychotics: case series and brief review of etiologic and treatment considerations. Drugs Context. 2014;3:212259.
   PubMedGoogle Scholar
• Teva Pharmaceuticals. Pimozide [package insert]. Sellersville (PA): Teva Pharmaceuticals; 2008.
   Google Scholar
• Rojo LE, Gaspar PA, Silva H, et al. Metabolic syndrome and obesity among users of second generation antipsychotics: a global challenge for modern psychopharmacology. Pharmacol Res. 2015;101:74–85.
   PubMed Web of Science ®Google Scholar
• Ricciardi L, Pringsheim T, Barnes TRE, et al. Treatment recommendations for tardive dyskinesia. Can J Psychiatry. 2019;64(6):388–399.
   PubMed Web of Science ®Google Scholar
• Waln O, Jankovic J. An update on tardive dyskinesia: from phenomenology to treatment. Tremor Other Hyperkinet Mov. 2013;3: 161–165.
   Google Scholar
• Agid O, Arenovich T, Sajeev G, et al. An algorithm-based approach to first-episode schizophrenia: response rates over 3 prospective antipsychotic trials with a retrospective data analysis. J Clin Psychiatry. 2011;72(11):1439–1444.
   PubMed Web of Science ®Google Scholar
• Lehman AF, Lieberman JA, Dixon LB, et al. Practice guideline for the treatment of patients with schizophrenia, second edition. Am J Psychiatry. 2004;161(2):1–56.
   PubMed Web of Science ®Google Scholar
• Fukasawa T, Takahashi M, Otani K. A successful clonazepam treatment without tolerance in a patient with spontaneous oral dyskinesia. Prog Neuropsychopharmacol Biol Psychiatry. 2001;25(7):1477–1480.
   PubMed Web of Science ®Google Scholar
• Thaker GK, Nguyen JA, Strauss ME, et al. Clonazepam treatment of tardive dyskinesia: a practical GABAmimetic strategy. Am J Psychiatry. 1990;147(4):445–451.
   PubMed Web of Science ®Google Scholar
• Hatcher-Martin JM, Armstrong KA, Scorr LM, et al. Propranolol therapy for tardive dyskinesia: a retrospective examination. Parkinsonism Relat Disord. 2016;32:124–126.
   PubMed Web of Science ®Google Scholar
• Cho C-H, Lee H-J. Oxidative stress and tardive dyskinesia: pharmacogenetic evidence. Prog Neuropsychopharmacol Biol Psychiatry. 2013;46:207–213.
   PubMed Web of Science ®Google Scholar
• Saltz BL, Robinson DG, Woerner MG. Recognizing and managing antipsychotic drug treatment side effects in the elderly. Prim Care Companion J Clin Psychiatry. 2004;6(2):14–19.
   PubMedGoogle Scholar
• Richardson MA, Bevans ML, Weber JB, et al. Branched chain amino acids decrease tardive dyskinesia symptoms. Psychopharmacology. 1999;143(4):358–364.
   PubMed Web of Science ®Google Scholar
• Bernstein AI, Stout KA, Miller GW. The vesicular monoamine transporter 2: an underexplored pharmacological target. Neurochem Int. 2014;73:89–97.
   PubMed Web of Science ®Google Scholar
• Abnormal Involuntary Movement Scale [Internet]. Chicago (IL): US Department of Health, Education and Welfare; 1976 [Cited 2021 January 2]. Available from: https://mmcp.health.maryland.gov/pap/docs/Abnormal%20Involuntary%20Movement%20Scale.pdf
   Google Scholar
• Neurocrine Biosciences. Valbenazine [package insert]. San Diego (CA): Neurocrine Biosciences Inc; 2017.
   Google Scholar
• Müller T. Valbenazine for the treatment of tardive dyskinesia. Expert Rev Neurother. 2017;17(12):1135–1144.
   PubMed Web of Science ®Google Scholar
• Touma KTB, Scarff JR. Valbenazine and deutetrabenazine for tardive dyskinesia. Innov Clin Neurosci. 2018;15(5–6):13–16.
   PubMedGoogle Scholar
• Dean L, et al. Deutetrabenazine therapy and CYP2D6 genotype. In: Pratt VM, Scott SA, Pirmohamed M, editors. Medical genetics summaries. Bethesda (MD): National Center for Biotechnology Information (US); 2012.
   Google Scholar
• Mullard A. FDA approves first deuterated drug. Nat Rev Drug Discov. 2017;16(5):305–305.
   Web of Science ®Google Scholar
• Claassen DO, Philbin M, Carroll B. Deutetrabenazine for tardive dyskinesia and chorea associated with Huntington’s disease: a review of clinical trial data. Expert Opin Pharmacother. 2019;20(18):2209–2221.
   PubMed Web of Science ®Google Scholar
• Wong JW, Koo JYM. Psychopharmacological therapies in dermatology. Dermatol Online J. 2013;19(5):18169.
   PubMedGoogle Scholar
• Brownstone N, Koo J. Why is pimozide uniquely useful for the treatment of delusional patients in dermatology? J Dermatolog Treat. 2020;1. doi:10.1080/09546634.2020.1825611
   Google Scholar
• Brownstone ND, Koo J. Special consideration for patients with Morgellons disease, even among psychodermatology patients? JAMA Dermatol. 2020;156(10):1142.
   PubMed Web of Science ®Google Scholar
• Frontline Medical Communications. Recent developments in psychodermatology and psychopharmacology for delusional patients [Internet]. Parsippany (NJ): Frontline Medical Communications Inc.; 2021 [Cited 2021 February 7]. Available from: https://www.mdedge.com/dermatology/article/234132/mixed-topics/recent-developments-psychodermatology-and-psychopharmacology?sso=true
   Google Scholar